nCounter® Inflammation Panel
Helping Your Research
Studying the early inflammatory response is fundamental to understanding the immune response and treating disease. The nCounter® Inflammation Panel lets you perform multiplex gene expression analysis on human or mouse samples with more than 200 genes focused on the study of inflammation. These genes represent a broad range of relevant pathways related to inflammation that include apoptosis, EGF, interleukin signaling, Ras, T cell receptor, and Toll-like receptor signaling. Panel highlights include:
- Content useful for the study of asthma, allergy, arthritis, and neurological-related inflammation
- Coverage of anti-inflammatory drugs that modulate the inflammatory response
- Overlapping coverage between Human and Mouse panels for direct species comparison
- Customizable with up to 55 additional user-defined genes with the Panel Plus option
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler
Breast cancer is a heterogenous disease with variability in tumor cells and in the surrounding tumor microenvironment (TME). Understanding the molecular diversity in breast cancer is critical for improving prediction of therapeutic response and prognostication.
Spatially organized multicellular immune hubs in human colorectal cancer.
Immune responses to cancer are highly variable, with mismatch repair-deficient (MMRd) tumors exhibiting more anti-tumor immunity than mismatch repair-proficient (MMRp) tumors. To understand the rules governing these varied responses, we transcriptionally profiled 371,223 cells from colorectal tumors and adjacent normal tissues of 28 MMRp and 34 MMRd individuals.
Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma.
Histiocytic sarcoma (HS) is a rare and aggressive tumor in humans with no universally agreed standard of care therapy. Spontaneous canine HS exhibits increased prevalence in specific breeds, shares key genetic and biologic similarities with the human disease, and occurs in an immunocompetent setting.